• 1
    Bitton A, Peppercorn M, Antonioli D, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120: 1320.
  • 2
    Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988; 10: 401405.
  • 3
    Fagan E, Dyck R, Maton P, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest. 1982; 12: 351359.
  • 4
    Linskens R, van Bodegraven A, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001; 46: 644648.
  • 5
    Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol. 1995; 30: 356360.
  • 6
    Niederau C, Backmerhoff F, Schumacher B, et al. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology. 1997; 44: 90107.
  • 7
    Nielsen O, Vainer B, Madsen S, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000; 95: 359367.
  • 8
    Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol. 1988; 10: 4145.
  • 9
    Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 661665.
  • 10
    Mazlam M, Hodgson H. Interrelations between interleukin-6, interleukin-1beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut. 1994; 35: 7783.
  • 11
    Schunk K, Kern A, Oberholzer K, et al. Hydro-MRI in Crohn's disease: appraisal of disease activity. Invest Radiol. 2000; 35: 431437.
  • 12
    Gomes P, du Boulay C, Smith C, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986; 27: 9295.
  • 13
    Rutgeerts P, Colombel J, Enns R, et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). Gut. 2003; 52: A239.
  • 14
    Sandborn W, Feagan B, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004; 53: 14851493.
  • 15
    Schreiber S, Rutgeerts P, Fedorak R, et al. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease. [abstract] Gastroenterology. 2003; 124 (suppl 1): A61.
  • 16
    Hanauer S, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001; 96: 635643.
    Direct Link:
  • 17
    Kornbluth A, Sachar D. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 13711385.
    Direct Link:
  • 18
    Shah S, Newby L. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev. 2003; 11: 169179.
  • 19
    Solem C, Loftus E Jr, Fletcher J, et al. Small Bowel (SB) Imaging in Crohn's Disease (CD): A Prospective, Blinded, 4-Way Comparison Trial [Abstract] Gastroenterology. 2005; 128: A74.